Enamine's Target-Agnostic Expertise in Biology, Drug Design, and Medicinal Chemistry Advances EMUNO Therapeutics Pipeline
Freiburg, Germany / Frankfurt, Germany / Kyiv, Ukraine / Wroclaw, Poland, 22 January 2026 – EMUNO Therapeutics reached critical R&D milestones with remarkable efficiency in their fight against cancer supported by the competence and Integrated Drug Discovery (IDD) Platform of the CRO Enamine. EMUNO and Enamine entered a comprehensive collaboration in June 2025 to advance EMUNO’s small molecule programs in immuno-oncology aimed at achieving clinical impact for challenging malignancies. EMUNO’s mission is to develop medicines which modulate specific immune responses in a controlled, pathway-specific approach to treat autoimmune disorders or overcome cancer immune evasion, and to enhance human health and wellbeing. The European Union supports their small molecule immune activator program with an EIC Transition Grant from the European Innovation Council. The IMMUNOCON project aims to advance the drug candidate EMT-224 towards clinical readiness to address the urgent need for effective therapies for refractory and treatment-resistant solid tumors, commonly seen in advanced/ late-stage cancer patients.
Enamine's agile IDD Platform of Computer-aided Drug Design (CADD), together with AI/ML approaches, innovative medicinal chemistry, and preclinical biology, including its capabilities in guiding structure-based drug design, fragment-based approaches as Enamine UFrag™, and Enamine's source of drug-relevant chemical space through the REAL compounds, enabled very short and effective design-make-test-analyze cycles across its research infrastructure.
Enamine’s profound knowledge of chemical space, namely with its REAL compounds, is the world’s largest collection of make-on-demand small molecules that represents a significant fraction of such synthetically accessible chemical space. Its member molecules are REadily AccessibLe through validated parallel synthesis protocols using qualified in-stock building blocks.
Enamine Germany in Frankfurt enables support of rapid lead optimization and project management. Enamine's capabilities in biology, from hit identification, lead optimization, and translating into preclinical proof-of-concept studies, are critically supported by its biology research centers in Kyiv and Wroclaw through their high-throughput screening, in vitro ADME, and in vivo PK/Tox, and other biological capabilities.
Dr. Emilia Neuwirt, Co-founder & CEO: As a young and innovative pharmaceutical start up, we are proud to collaborate with Enamine, who has proven to deliver comprehensive support and outstanding resource optimization. Enamine’s fully integrated platform for optimized lead generation, combined with their scientific rigor, operational excellence, and extensive R&D ecosystem, has enabled us to reach critical milestones with remarkable efficiency.
Prof. Dr. Olaf Groß, Co-founder & CSO at EMUNO Therapeutics added: We are proud to work with such a trusted and innovative partner driving real impact in drug discovery.
Sven Wagner, PhD, Vice President of Partnerships at Enamine: We are honored to continue our collaboration with EMUNO in 2026 by dovetailing Enamine's IDD Platform with EMUNO's drug discovery infrastructure. We are highly impressed by EMUNO's profound competence in immuno-oncology based on ground-breaking science, and their team's ease and professional attitude for working together, always with the needs of patients in mind.
Dr. Ivan Kondratov, Head of Medicinal Chemistry at Enamine Germany added: In this inspiring collaboration, the joint EMUNO and Enamine team was able to establish a highly productive and cost-effective hit-to-lead optimization with short DMTA cycles. This is an excellent example of a seamless Biotech-CRO collaboration. We are highly motivated to push forward with further ambitious goals together.